NCT05676476

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 132 (estimated)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: Female
• Age: 14 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

Detailed description

Hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia, are characterized by new onset high blood pressure in pregnancy and constitute a major cause of maternal and perinatal morbidity and mortality; severe hypertension (blood pressure ≥160/110 mmHg) is a common trigger for antihypertensive treatment and preterm delivery. We propose a clinical trial that will test whether lowering the blood pressure in women with hypertensive disorders of pregnancy at \<36 weeks' gestation to \<140/90 mmHg will prolong pregnancy and, therefore, improve maternal and fetal/neonatal outcomes. Data generated in this study, along with knowledge and skills acquired by the candidate in the complementary career development plan, will facilitate an independent research career focused on hypertension and cardiovascular disease in pregnancy.

Conditions

• Preeclampsia
• Gestational Hypertension
• Hypertensive Disorder of Pregnancy

Interventions

Type	Name	Description
DRUG	Antihypertensive treatment	Antihypertensive treatment to goal of less than 140/90 mmHg

Timeline

• Start date: 2023-02-14
• Primary completion: 2026-12-01
• Completion: 2027-06-01
• First posted: 2023-01-09
• Last updated: 2025-12-12

Locations

2 sites across 1 country: United States